These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33827280)

  • 1. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
    Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
    Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
    Park JC; Krishnakumar HN; Saladi SV
    Curr Oncol; 2022 Jun; 29(6):4185-4198. PubMed ID: 35735443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The research progress of PD-1/L1 inhibitors application in the treatment of head and neck squamous cell carcinoma].
    Song P; Yan X; Jiang Y; Ye Y; Wang J; Han P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Apr; 36(4):315-320. PubMed ID: 35511629
    [No Abstract]   [Full Text] [Related]  

  • 7. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
    Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
    Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
    Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
    Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
    Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
    Huang S; Xiong C; Tan K
    Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
    Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
    Park R; Park JC
    Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.